Of is the key to prevention of

2008 Hong Kong-Shanghai International Conference on liver disease (ILC 2008), the General Assembly President academician Tang Zhaoyou and Japan surgical society President Professor Morito Monden co-chaired the "China-Japan Forum", on the prevention of postoperative recurrence of liver cancer treatment for presentations and discussion.　　Shanghai Zhongshan Hospital of Fudan University, Associate Professor Sun huichuan are invited on this "China-Japan Forum" summary author, share with readers. Sun huichuan Shanghai Institute of Fudan University Zhongshan Hospital of liver cancer treatment to prevent recurrence after resection of hepatocellular carcinoma based on treatment of hepatocellular carcinoma lesions, divided into resectable hepatocellular carcinoma patients and patients with unresectable liver cancer.　　The former most promising long-term survival, it is critical for preventing recurrent treatment. At present, although hepatectomy for liver cancer has become a safe and effective treatments, but the recurrence rate is still as high as 40%~60%, seriously affecting the patient's survival of the extension.　　Liu Yunyi academicians of the Chinese University of Hong Kong introduced the risk factors for postoperative recurrence of liver cancer, and review the various measures that have been reported in the current literature, including systemic chemotherapy, treatment of local chemotherapy embolism, Retinoic acid, cytokine-activated killer cells (LAK cell) therapy, interferon, and so on. Academician of lipiodol in treatment of 131I labeled Liu Yunyi highlights iodine (131I) marking of lipiodol in treatment, considered this treatment can significantly improve patient survival. Included in the study of 43 patients with liver cancer, patients are accepting of radical resection. 21 cases of postoperative received 131I labeled within 6 weeks of lipiodol in hepatic artery infusion therapy. Results show that disease-free survival period of treatment and control groups were 57.2 and 13.6 month, 3-year overall survival rate and 84.6%, respectively.　　This research result also earned two France team support. Interferon treatment such as Zhongshan Hospital of Fudan University in Shanghai, Sun huichuan a study include acceptance of 236 cases of radical resection of liver cancer patients, of which 118 receiving interferon treatment to prevent relapse.　　Results showed that interferon treatment, and disease-free survival in patients with non-treatment group were 31.2 and 17.7 months, 63.8 per cent and 38.8-month overall survival. At present, worldwide, a total of 7 on interferon to prevent liver cancer recurrence of random group, support the foregoing findings of the study. History of HBV in patients with liver cancer, interferon is mainly inhibit residual tumor growth, and for a history of hepatitis c in patients with liver cancer, interferon in the treatment of major regeneration to reduce liver cancer.　　Associate Professor Sun huichuan also introduced a series of basic research on interferon in treatment of liver cancer, prompted tumors P48-positive patients receiving interferon therapy suitable objects. Interferon combined with chemotherapy medication Japan Tokushima University Shimada, combination treatment with interferon and chemotherapeutic drugs 5-fluorouracil and cisplatin prevention associated with tumor thrombus in hepatocellular carcinoma patients with postoperative recurrence to the naked eye. Results show that treatment group and 3-year survival rate of non-treatment group and 63.5%, respectively. While this study into the number of cases limited (25 patients), but the results are encouraging.　　This study suggests, combination of interferon and chemotherapeutic drugs for more advanced types of postoperative recurrence of liver cancer, there may be a better preventive effect. Japan, Tokyo University of Hepatobiliary and pancreatic surgery Hasegawa introduced after hepatectomy of oral chemotherapy drug to prevent recurrence.　　Result again, simple oral chemotherapy drug fluorouracil tegafur, on preventi